EcoDrugPlus

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSNNAG00000000753
Gene Symbol: MAPK14
1 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSNNAG00000013555
Gene Symbol: MAPK8
1 Cross references
294 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSNNAG00000015812
Gene Symbol: MAPK9
1 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSNNAG00000010963
Gene Symbol: MAP2K1
1 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSNNAG00000012384
Gene Symbol: MAP3K1
1 Cross references
160 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSNNAG00000006874
Gene Symbol: MAP3K11
1 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSNNAG00000008985
Gene Symbol: MAP3K12
1 Cross references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSNNAG00000016254
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSNNAG00000002163
Gene Symbol: MAP3K5
1 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSNNAG00000016730
Gene Symbol: MAP3K8
1 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSNNAG00000013526
Gene Symbol: MAP3K9
1 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Monoamine Oxidase A

Ensembl ID : ENSNNAG00000007840
Gene Symbol: MAOA
1 Cross references
148 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).